bioinnovationbeacon.com

Author: Nick Paul Taylor

  • Reusing data could cut R&D costs and greatly increase gene editing’s reach: ARM

    Reusing data could cut R&D costs and greatly increase gene editing’s reach: ARM

    The gene-editing space has a new playbook aimed at radically reducing the work needed to bring these therapies to the clinic.

    Building on the FDA’s draft guidance published this summer, the advocacy organization Alliance for Regenerative Medicine (ARM) has set out how developers can reuse data to eliminate redundant studies and drive down costs. ARM argues that by reusing data, developing genetic medicines for ultrarare diseases can be viable even though these indications affect too few patients to generate a return on typical R&D budgets.

    “If we can leverage the platform and make the cost of the incremental effort to treat a mutation very minimal, rare disease patients suddenly get this kind of therapy where they wouldn’t have otherwise,” John Evans, CEO of Beam Therapeutics, which was involved in creating the playbook, told BioSpace.

    While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets, analysts said that Beam might have the efficacy advantage as Wave’s drug hits an efficacy “ceiling.”

    May 20, 2026

     · 

    2 min read

     · 

    Implementing the platform approach

    ARM’s playbook, published late last month, provides a guide for developers seeking to reuse data to streamline drug development. Josephine Lembong, ARM’s associate director for scientific affairs, outlined the first steps for developers that want to implement the proposed plan.

    “First, developers should decide on their main objective,” Lembong told BioSpace via email. “Especially for rare diseases, that goal may be rapid clinical proof of concept, full licensure or long-term commercial viability, and the choice should factor in population size, unmet need and the availability of alternative treatments.”

    Whatever the objective, Lembong recommended preparing for a regulatory filing from the outset, designing and building programs for a potential submission. That approach aligns with how Beam operates under Evans, who said that the biotech designs Phase 1 trials to be registrational. In doing so, Beam aims to go from first-in-human trials to FDA approval in four to five years, compared to eight to 10 years in the traditional clinical pathway.

    In parallel with discussions of their main objectives, Lembong said developers should shape their regulatory strategy by mapping their programs to existing FDA frameworks and guidance. At the same time, she added, companies should “define the platform’s scientific boundaries, distinguishing its fixed components from its variable ones.”

    Fixed and variable components “depend on the target disease and its known mutations,” Lembong explained. The delivery vehicle, route and formulation may be fixed, allowing developers to reuse data. In contrast, guide-specific biology cannot be assumed from the first product and should be evaluated directly.

    Reusing data

    Acute toxicity studies offer the biggest opportunity to reuse data under the platform model, Evans said. A lipid nanoparticle will trigger “the exact same acute toxicity outcome” when the payload is adapted to a new target mutation, he continued, making repeat studies redundant.

    Chemistry, manufacturing and controls tasks provide further opportunities to reuse data. Such tasks are “a huge amount of the overhead in genetic medicine,” Evans said, reflecting the complexity of the drugs. Under the platform approach, he said, Beam can “use the same assays every time and we know exactly what we’re going to get.”

    Those opportunities apply to a range of genetic medicines, but Evans sees further streamlining opportunities that are “somewhat more unique” to Beam’s base-editing method. Companies could use the plausible mechanism pathway, which the FDA unveiled last year, to stop generating animal data in each genetic driver of a disease that may have many such drivers, Evans said. He highlighted phenylketonuria (PKU), for which Beam is actively pursuing a treatment, as being caused by hundreds of variants.

    The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed.

    November 13, 2025

     · 

    3 min read

     · 

    After reusing safety, efficacy and manufacturing data, developers will have short lists of product-specific tasks that they need to perform every time. Beam will need to show every new editor is potent enough, which can often be done in cells, Evans said. Beyond that, companies will continue to run on- and off-target editing studies.

    “That might be 10% of the work of a full package. Everything else is cross-referenced to studies we’ve already run,” Evans said. Investigational new drug (IND) applications “are now effectively platform INDs where multiple edits can live together, all trying to deliver the same functional outcome on the gene and on the patient. That’s the really novel part of this.”

    Further enhancements

    The platform model alone “may not be sufficient to fully address the cost and access challenges facing the field,” ARM said in its playbook. This concern led ARM to conclude its report with a call for “a broader discussion of whether certain traditional development expectations should be modified, abbreviated or, in carefully justified cases, removed altogether”—when risks are low and potential benefits are high.

    ARM argued that existing accelerated clinical development pathways are “untenable” for many sponsors in the rare and ultrarare disease space. Developing drugs for diseases that affect very small numbers of patients or are especially severe or urgent will “require a higher appetite for risk,” ARM said.

    The group proposed a bifurcated regulatory framework allowing higher-risk, streamlined development of treatments for severe rare diseases that have no standard of care. ARM’s push to further streamline development is part of a broader focus on maximizing genetic medicine’s impact.

    “We don’t want to look up in five or 10 years and see that we’ve done this once or twice. We want to have done this 10, 20, 100 times,” Evans said. “There’s a direct line from the efficiency with which we can move these products through the regulatory process . . . and how many diseases we can tackle.”

  • Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events

    Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events

    The FDA has accused Fresenius Kabi of failing to sufficiently investigate a critical manufacturing deviation linked to reports of adverse events.

    FDA inspectors spent three weeks at Fresenius Kabi’s manufacturing facility in Melrose Park, Illinois, earlier this year. The investigators found fault with Fresenius Kabi’s response to reports of adverse events in patients injected with famotidine, an H2 blocker used to treat heartburn and stomach ulcers, the FDA explained in a warning letter published Tuesday.

    The reports included apparent pyrogenic reactions, a medical term for fever. Pyrogen contamination to injectable drug products can lead to significant adverse events such as fever, hypotension, inflammatory reactions, anaphylactic shock or death, the FDA told Fresenius Kabi.

    The company’s famotidine injection manufacturing surpassed multiple bioburden action limits, the FDA said. The agency found Fresenius Kabi “failed to sufficiently investigate this critical deviation and permitted batch release following passing finished drug product test results.” Subsequent testing in response to the adverse events revealed an endotoxin failure and triggered a recall of three famotidine batches.

    No patient safety concerns have been identified, a Fresenius Kabi spokesperson told BioSpace via email. The spokesperson said the facility “remains operational, and at this time we do not anticipate significant disruptions to the supply of products currently on the market,” adding that the company “is taking the necessary actions to address [the FDA’s observations] thoroughly and responsibly.”

    The FDA deemed Fresenius Kabi’s initial response inadequate. Replying in March to the FDA’s Form 483, the company acknowledged that bioburden samples showed Gram-negative confluent growth, indicating that a lawn of bacteria covered the surface of the test medium. Fresenius Kabi did not consider the excessive bioburden, meaning the number of bacteria, an elevated endotoxin risk, the FDA said. Endotoxins are parts of bacteria that can activate the immune system, causing adverse events.

    While Fresenius Kabi vowed to enhance endotoxin sampling and testing, the FDA called out the company for failing to commit to a comprehensive review of its complaint system to increase vigilance. The FDA wants Fresenius Kabi to maintain ongoing, robust upstream control, adding that “any batch testing that reveals atypical bioburden levels is a signal that necessitates prompt attention.”

    The FDA also criticized Fresenius Kabi’s handling of media fill failures and the discovery of hair in drug products. Fresenius Kabi determined that operators’ deficient aseptic techniques could have contributed to media fill failures. The company’s investigations “did not consider how the poor aseptic practices went undetected by your firm’s aseptic observer program during commercial operations,” the FDA said.

    FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”

    September 24, 2026

     · 

    2 min read

     · 

    Starting in May 2022, Fresenius Kabi documented at least nine cases of extrinsic contamination during its visible particulate inspection. The FDA named hair as an example of an extrinsic contaminant.

    “This contamination was described as free-floating and in direct contact with the drug product,” the FDA said. “Drug products contaminated with hair can have microbial contamination and are generally considered adulterated. You did not initiate timely investigations in response to this contamination.”

    The FDA, which sent the warning letter on Sept. 22, gave Fresenius Kabi 15 business days to respond. Remediations are underway at the site, the spokesperson said.